Gavi outlines plans to support access to new vaccines
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
The award recognizes powerful science–industry collaborations for social good
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
The demand in Africa for COVID-19 vaccines has declined
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Subscribe To Our Newsletter & Stay Updated